NOVADIP is a Belgium-based company that developed a unique bone therapy with a first in class single treatment cure for long-term union/stability of critical size bone defects saving limbs and avoiding amputations (NVD003 – Autologous cell-based product) along with an allogenic cell-derived “off-the-shelf” product for spine fusion (NVDX3). NVD003 will be the scope for the next financing round of €87M.